Advertisement

Tumor Biology

, Volume 37, Issue 1, pp 1017–1023 | Cite as

Vascular endothelial growth factor polymorphisms and a synchronized examination of plasma and tissue expression in epithelial ovarian cancers

  • J. Bhaskari
  • C. S. Premalata
  • V. Shilpa
  • B. Rahul
  • V. R. Pallavi
  • G. Ramesh
  • Lakshmi Krishnamoorthy
Original Article
  • 131 Downloads

Abstract

In this study, we have analyzed six genetic polymorphisms of the VEGF-A gene and correlated the genetic data with plasma and tissue expression of VEGF-A in epithelial ovarian carcinomas. A total of 130 cases including 95 malignant carcinomas, 17 low malignant potential and 18 benign tumours were studied. rs699947, rs833061, rs1570360, rs2010963, rs1413711 and rs3025039 were studied by polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). Plasma levels of VEGF-A were estimated by enzyme-linked immunosorbent assay (ELISA) and tissue expression of VEGF-A by immunohistochemistry (IHC). Four polymorphisms of the above excluding rs699947 and rs3025039 showed significant association with malignancy, and we observed the presence of positive correlation between haplotype CCGGCC and increased expression of VEGF-A in both plasma and tissues which also correlated with poor prognosis and recurrence suggesting a probable increase in resistance to treatment in such carriers. Highly upregulated tissue expression of VEGF-A was seen in all epithelial ovarian carcinomas with intensity of expression increasing from benign to malignant cases. ELISA data from our study showed an increase in circulating levels of VEGF-A in malignancies. VEGF-A plasma levels can be employed as a biomarker for high-grade malignancy in epithelial ovarian cancers alongside tissue expression and CA-125 levels. This study is unique due to the fact that a simultaneous analysis of plasma and tissue expression has been demonstrated and is a first such study in epithelial ovarian cancers and representing the Indian population (South-east Asian) synchronized with genetic polymorphism data as well.

Keywords

VEGF SNPs VEGF Polymorphisms Linkage Haplotypes Plasma levels of VEGF-A Tissue expression of VEGF-A Simultaneous study of plasma levels and tissue expression of VEGF-A 

Notes

Acknowledgments

The work was financially supported by the Indian Council of Medical Research, New Delhi, India. Reference number 5/13/28/2010/NCD-III.

Conflicts of interest

None

Supplementary material

13277_2015_3891_MOESM1_ESM.doc (44 kb)
Table S1 Demographic details of cases recruited. (DOC 44 kb)
13277_2015_3891_MOESM2_ESM.doc (30 kb)
Table S2 PCR primers and respective annealing temperatures of SNPs (DOC 30 kb)
13277_2015_3891_MOESM3_ESM.doc (34 kb)
Table S3 An analysis of the polymorphisms under the dominant and recessive models. (DOC 34 kb)
13277_2015_3891_MOESM4_ESM.doc (26 kb)
Figure S1 LD plot depicting linkage between studied polymorphisms (DOC 26 kb)

References

  1. 1.
    Crawford Y, Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res. 2009;335:261–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Jain L, Vargo CA, Danesi R. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumours. MCR. 2009;10:1158–535.Google Scholar
  3. 3.
    Zarbock R, Hendig D, Szliska C, Kleesiek K, Gotting C. Vascular endothelial growth factor gene polymorphisms as prognostic markers for ocular manifestations in pseudoxanthoma elasticum. Hum Mol Genet. 2009;18:3344–51.CrossRefPubMedGoogle Scholar
  4. 4.
    Seo JS, Lee SS, Kim SI, Ryu WH, Sa KH, et al. Influence of VEGF gene polymorphisms on the severity of ankylosing spondylitis. Rheumatology. 2005;44:1299–302.CrossRefPubMedGoogle Scholar
  5. 5.
    Yang X, Deng Y, Gu H, Lim A, Altankhuyag A, et al. Polymorphisms in the vascular endothelial growth factor gene and the risk of diabetic retinopathy in Chinese patients with type 2 diabetes. Mol Vis. 2011;17:3088–96.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer. 1988;34(13):2041–5.CrossRefGoogle Scholar
  7. 7.
    Ferrero S. Serum and plasma vascular endothelial growth factor levels in testicular cancer patients. Ann Oncol. 2004;15(6):989–90.CrossRefPubMedGoogle Scholar
  8. 8.
    Luigi M, Elena R, Sergio M, Elitza N, Irene F, Angela G, et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumour progression and response to therapy. Mol Cancer Ther. 2005;4(5):715–25.CrossRefGoogle Scholar
  9. 9.
    Lawicki S, Bedkowska GE, Szumarska EG, Szmitkowski M. The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumours. J Ovarian Res. 2013;6:45.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Siddiqui GK, Maclean AB, Elmasry K, Wong te Fong A, Morris RW, Rashid M, et al. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer. Angiogenesis. 2011;14(2):155–61.CrossRefPubMedGoogle Scholar
  11. 11.
    Langsenlehner T, Langsenlehner U, Renner W, Krippl P, Mayer R, Wascher TC, et al. Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. Eur J Cancer. 2008;44:1572–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, Nikiteas N, et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog. 2009;48(6):563–9Google Scholar
  13. 13.
    Sfar S, Hassen E, Saad H, Mosbah F, Chouchane L. Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine. 2006;35:21–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res. 2005;11:3647–53.CrossRefPubMedGoogle Scholar
  15. 15.
    Heist RS, Zhai R, Liu G, Zhou W, Lin X, Su L, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:856–62.CrossRefPubMedGoogle Scholar
  16. 16.
    Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol. 2010;117(1):109–16Google Scholar
  17. 17.
    Lose F, Nagle CM, O’Mara T, Batra J, Bolton KL, Song H. Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecol Oncol. 2010;119:479–83.CrossRefPubMedGoogle Scholar
  18. 18.
    Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 2002;62:4123–31.PubMedGoogle Scholar
  19. 19.
    Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 2004;64:7822–35.CrossRefPubMedGoogle Scholar
  20. 20.
    Varey AH, Rennel ES, Qiu Y, Bevan HS, Perrin RM, et al. VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br J Cancer. 2008;98:1366–79.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • J. Bhaskari
    • 1
  • C. S. Premalata
    • 2
  • V. Shilpa
    • 1
  • B. Rahul
    • 1
  • V. R. Pallavi
    • 3
  • G. Ramesh
    • 1
  • Lakshmi Krishnamoorthy
    • 1
    • 4
  1. 1.Department of BiochemistryKidwai Memorial Institute of OncologyBangaloreIndia
  2. 2.Department of PathologyKidwai Memorial Institute of OncologyBangaloreIndia
  3. 3.Department of Gynec-OncologyKidwai Memorial Institute of OncologyBangaloreIndia
  4. 4.Department of BiochemistrySri Shankara Cancer Hospital and Research CentreBangaloreIndia

Personalised recommendations